SEO

December 9, 2021

"We are no longer giving Adequate Healthcare to these patients" — FMOLHS Chief Medical Officer, Dr. Catherine O'Neal [Jolee Bollinger, EVP General Counsel] CORPORATE RESPONSIBILITY AND CORPORATE COMPLIANCE (Legal risk may exist based on failing to provide professional standard of quality)

 



"We are *no longer giving Adequate Healthcare to these patients."

— Dr. Catherine O'Neal American Medical Association Office of the Chief Records Officer for the US Government and Infectious Diseases Society of America Centers for Disease Control and Prevention expert



Jolee Bollinger, EVP General Counsel FMOLHS


*^Jolee balances

operational aspects IHS

corporate integrity

commitment mission

serving in need


Thank you, Jolee, for *ensuring we continually operate at the highest level of professionalism and compassion.


*Dr. Catherine O'Neal

 "We are *no longer giving ADEQUATE CARE to these patients" 

 chief medical officer, infectious disease expert



*Daryl Allen, CHC, CHPC

Healthcare Compliance Privacy Officer

FMOLHS



*no longer giving Adequate Healthcare to these patients.

^ensuring we continually operate at the highest level of professionalism and compassion

CORPORATE RESPONSIBILITY AND CORPORATE COMPLIANCE: A Resource for Health Care Boards of Directors THE OFFICE OF INSPECTOR GENERAL OF THE U S DEPARTMENT OF HEALTH AND HUMAN SERVICES AND THE AMERICAN HEALTH LAWYERS ASSOCIATION

 

Daryl Allen, CHC, CHPC

Franciscan Missionaries of Our Lady Health System
Director, Compliance and Privacy Officer
March 2014 - Present (7 years 10 months)
Louisiana State University
Bachelor of Science, Finance · (2000)


CORPORATE RESPONSIBILITY AND CORPORATE COMPLIANCE

 I INTRODUCTION 

As corporate responsibility issues fill the headlines, corpo­ rate directors are coming under greater scrutiny.

The Sarbanes-Oxley Act, state legislation, agency pronouncements, court cases and scholarly writings offer a myriad of rules, regulations, prohibitions, and interpretations in this area.

While all Boards of Directors must address these issues, directors of health care organizations also have important responsibilities that need to be met relating to corporate compliance requirements unique to the health care industry.

The expansion of health care regulatory enforcement and compliance activities and the height attention being given to the responsibilities of corpo directors are critically important to all health care organizations.

In this context, enhanced oversight of cor­ compliance programs is widely viewed as consistent with and essential to ongoing federal and state corporate responsibility initiatives.

Our complex health care system needs dedicated and knowledgeable directors at the helm of both for-profit and non-profit corporations.

This educational resource, co­ sponsored by the Office of Inspector General (OIG) of the U S Department of Health and Human Services and the American Health Lawyers Association, the leading health law educational organization, seeks to assist directors of health care organizations in carrying out their important oversight responsibilities in the current chal­ lenging health care environment.

Improving the knowl­edge base and effectiveness of those serving on health care organization boards will help to achieve the important goal of continuously improving the U S health care system.

Fiduciary Responsibilities The fiduciary duties of directors reflect the expectation of corporate stakeholders regarding oversight of corporate affairs.

The basic fiduciary duty of care principle, which requires a director to act in good faith with the care an ordinarily prudent person would exercise under similar circumstances, is being tested in the current corporate climate.

Personal liability for directors, including removal, civil damages, and tax liability, as well as damage to reputa­ tion, appears not so far from reality as once widely believed.

Accordingly, a basic understanding of the direc­tor’s fiduciary obligations and how the duty of care may be exercised in overseeing the company’s compliance systems has become essential.

Embedded within the duty of care is the concept of reasonable inquiry.

In other words, directors should make inquiries to management to obtain information necessary to satisfy their duty of care.

V

 

SUGGESTED QUESTIONS FOR DIRECTORS  

Periodic consideration of the following questions and commentary may be helpful to a health care organiza­ tion’s Board of Directors.

The structural questions explore the Board’s understanding of the scope of the organiz’s compliance program.

The remaining questions, addressing operational issues, are directed to the operations of the compliance program and may facilitate the Board’s understanding of the vitality of its compliance program.

STRUCTURAL QUESTIONS

 

1.

How is the compliance program structured and who are the key employees responsible for its implementation and operation?

How is the Board structured to oversee compliance issues?

The success of a compliance program relies upon assigning high-level personnel to oversee its implementation and operations.

The Board may wish as well to establish a com­ mittee or other subset of the Board to monitor compliance program operations and regularly report to the Board. 2.

How does the organization’s compliance reporting system work?

How frequently does the Board receive reports about compliance issues?

Although the frequency of reports on the status of the com­ pliance program will depend on many circumstances, health care organization Boards should receive reports on a regular basis.

Issues that are frequently addressed include (1) what the organization has done in the past with respect to the program and (2) what steps are planned for the future and why those steps are being taken. 3.

What are the goals of the organization’s compli­ ance program?

What are the inherent limita­ tions in the compliance program?

How does the organization address these limitations?

The adoption of a corporate compliance program by an organization creates standards and processes that it should be able to rely upon and against which it may be held accountable.

A solid understanding of the rationale and objectives of the compliance program, as well as its goals and inherent limitations, is essential if the Board is to eval­ uate the reasonableness of its design and the effectiveness of its operation.

If the Board has unrealistic expectations of its compliance program, it may place undue reliance 4 on its ability to detect vulnerabilities.

Furthermore, com­ pliance programs will not prevent all wrongful conduct and the Board should be satisfied that there are mecha­nisms to ensure timely reporting of suspected violations and to evaluate and implement remedial measures.  

4.

Does the compliance program address the significant risks of the organization?

How were those risks determined and how are new compliance risks identified and incorporated into the program?

Health care organizations operate in a highly regulated industry and must address various standards, government program conditions of participation and reimbursement, and other standards applicable to corporate citizens irre­ spective of industry.

A comprehensive ongoing process of compliance risk assessment is important to the Board’s awareness of new challenges to the organization and its evaluation of management’s priorities and program resource allocation. 

5.

What will be the level of resources necessary to implement the compliance program as envisioned by the Board?

How has management determined the adequacy of the resources dedicated to implementing and sustaining the compliance program?

From the outset, it is important to have a realistic under- standing of the resources necessary to implement and sus­ tain the compliance program as adopted by the Board.

The initial investment in establishing a compliance infra­ structure and training the organization’s employees can be significant.

With the adoption of a compliance program, the organization is making a long term commitment of resources because effective compliance systems are not static programs but instead embrace continuous improve­ ment.

Quantifying the organization’s investment in com­ pliance efforts gives the Board the ability to consider the feasibility of implementation plans against compliance program goals.

Such investment may include annual budgetary commitments as well as direct and indirect human resources dedicated to compliance.

To help ensure that the organization is realizing a return on its compliance investment, the Board also should consider how management intends to measure the effectiveness of its compliance program.

One measure of effectiveness may be the Board’s heightened sensitivity to compliance risk areas.

OPERATIONAL QUESTIONS The following questions are suggested to assist the Board in its periodic evaluation of the effectiveness of the organi­ zation’s compliance program and the sufficiency of its reporting systems.

A Code of Conduct How has the Code of Conduct or its equivalent been incorporated into corporate policies across the organiza­ tion?

How do we know that the Code is understood and accepted across the organization?

Has management taken affirmative steps to publicize the importance of the Code to all of its employees?

Regardless of its title, a Code of Conduct is fundamental to a successful compliance program because it articulates the organization’s commitment to ethical behavior.

The Code should function in the same way as a constitution, i e , as a document that details the fundamental principles, values, and framework for action within the organization.

The Code of Conduct helps define the organization’s cul­ ture; all relevant operating policies are derivative of its prin­ ciples.

As such, codes are of real benefit only if meaningfully communicated and accepted throughout the organization.

B Policies and Procedures Has the organization implemented policies and procedures that address compliance risk areas and established internal controls to counter those vulnerabilities?

If the Code of Conduct reflects the organization’s ethical philosophy, then its policies and procedures represent the organization’s response to the day-to-day risks that it con- fronts while operating in the current health care system.

These policies and procedures help reduce the prospect of erroneous claims, as well as fraudulent activity by identi­ fying and responding to risk areas.

Because compliance risk areas evolve with the changing reimbursement rules and enforcement climate, the organization’s policies and procedures also need periodic review and, where appropriate, revision. 

4 Regular consultation with counsel, including reports to the Board, can assist the Board in its oversight responsibilities in this changing environment. 

4 There are a variety of materials available to assist health care organizations in this regard.

For example, both sponsoring organizations of this educational resource offer various materials and guidance, accessible through their web sites.

 

5 CORPORATE RESPONSIBILITY AND CORPORATE COMPLIANCE 

C

 

Compliance Infrastructure 

1.

Does the Compliance Officer have sufficient authority to implement the compliance program?

Has management provided the Compliance Officer with the autonomy and sufficient resources necessary to perform assessments and respond appropriately to misconduct?

Designating and delegating appropriate authority to a com­ pliance officer is essential to the success of the organiza­ tion’s compliance program.

For example, the Compliance Officer must have the authority to review all documents and other information that are relevant to compliance activities.

Boards should ensure that lines of reporting within man­ agement and to the Board, and from the Compliance Officer and consultants, are sufficient to ensure timely and candid reports for those responsible for the compliance program.

In addition, the Compliance Officer must have sufficient personnel and financial resources to implement fully all aspects of the compliance program. 2.

Have compliance-related responsibilities been assigned across the appropriate levels of the organization?

Are employees held accountable for meeting these compliance-related objectives during performance reviews?

The successful implementation of a compliance program requires the distribution throughout the organization of compliance-related responsibilities.

The Board should sat­isfy itself that management has developed a system that establishes accountability for proper implementation of the compliance program.

The experience of many organi­ zations is that program implementation lags where there is poor distribution of responsibility, authority and accountability beyond the Compliance Officer.

D Measures to Prevent Violations 1.

What is the scope of compliance-related education and training across the organization?

Has the effectiveness of such training been assessed?

What policies/measures have been developed to enforce training requirements and to provide remedial training as warranted?

A critical element of an effective compliance program is a system of effective organization-wide training on compli­ ance standards and procedures.

In addition, there should be specific training on identified risk areas, such as claims development and submission, and marketing practices.

Because it can represent a significant commitment of resources, the Board should understand the scope and effectiveness of the educational program to assess the return on that investment.

2.

How is the Board kept apprised of significant regulatory and industry developments affecting the organization’s risk?

How is the compliance program structured to address such risks?

The Board’s oversight of its compliance program occurs in the context of significant regulatory and industry devel­ opments that impact the organization not only as a health care organization but more broadly as a corporate entity.

Without such information, it cannot reasonably assess the steps being taken by management to mitigate such risks and reasonably rely on management’s judgment. 

3.

How are “at risk” operations assessed from a compliance perspective?

Is conformance with the organization’s compliance program periodically evaluated?

Does the organization periodically evalu­ ate the effectiveness of the compliance program?

Compliance risk is further mitigated through internal review processes.

Monitoring and auditing provide early identification of program or operational weaknesses and may substantially reduce exposure to government or whistleblower claims.

Although many assessment tech­niques are available, one effective tool is the performance of regular, periodic compliance audits by internal or exter­ nal auditors.

In addition to evaluating the organization’s conformance with reimbursement or other regulatory rules, or the legality of its business arrangements, an effec­ tive compliance program periodically reviews whether the compliance program’s elements have been satisfied.

 4.

What processes are in place to ensure that appropriate remedial measures are taken in response to identified weaknesses?

Responding appropriately to deficiencies or suspected non-compliance is essential.

Failure to comply with the organization’s compliance program, or violation of appli­ cable laws and other types of misconduct, can threaten the organization’s status as a reliable and trustworthy provider of health care.

Moreover, failure to respond to a known deficiency may be considered an aggravating cir­ cumstance in evaluating the organization’s potential liabil­ ity for the underlying problem. 

E Measures to Respond to Violations 

1.

What is the process by which the organization evaluates and responds to suspected compliance violations?

How are reporting systems, such as the compliance hotline, monitored to verify appropriate resolution of reported matters?

Compliance issues may range from simple overpayments to be returned to the payor to possible criminal violations.

The Board’s duty of care requires that it explore whether procedures are in place to respond to credible allegations of misconduct and whether management promptly initi­ ates corrective measures.

Many organizations take discipli­nary actions when a responsible employee’s conduct vio­ lates the organization’s Code of Conduct and policies.

Disciplinary measures should be enforced consistently. 

2.

Does the organization have policies that address the appropriate protection of “whistleblowers” and those accused of misconduct?

For a compliance program to work, employees must be able to ask questions and report problems.

In its fulfill­ ment of its duty of care, the Board should determine that the organization has a process in place to encourage such constructive communication. 

3.

What is the process by which the organization evaluates and responds to suspected compliance violations?

What policies address the protection of employees and the preservation of relevant documents and information?

Legal risk may exist based not only on the conduct under scrutiny, but also on the actions taken by the organization in response to the investigation.
In addition to a potential obstruction of a government investigation, the organiza­ tion may face charges by employees that it has unlawfully retaliated or otherwise violated employee rights.

It is important, therefore, that organizations respond appropriately to a suspected compliance violation and, more critically, to a government investigation without damaging the corporation or the individuals involved.

The Board should confirm that processes and policies for such responses have been developed in consultation with legal counsel and are well communicated and understood across the organization. 

4.

What guidelines have been established for reporting compliance violations to the Board?

As discussed, the Board should fully understand management’s process for evaluating and responding to identified violations of the organization’s policies, as well as applica­ ble federal and state laws.

In addition, the Board should receive sufficient information to evaluate the appropriate­ ness of the organization’s response. 

5.

What policies govern the reporting to government authorities of probable violations of law?

Different organizations will have various policies for investigating probable violations of law.

Federal law encourages organizations to self-disclose wrongdoing to the federal government.

Health care organizations and their counsel have taken varied approaches to making such disclosures.

Boards may want to inquire as to whether the organiza­ tion has developed a policy on when to consider such disclosures.

VI.

Conclusion  

The corporate director, whether voluntary or compensat­ ed, is a bedrock of the health care delivery system.

The oversight activities provided by the director help form the corporate vision, and at the same time promote an environ­ ment of corporate responsibility that protects the mission of the corporation and the health care consumers it serves.

Even in this “corporate responsibility” environment, the health care corporate director who is mindful of his/her fundamental duties and obligations, and sensitive to the premises of corporate responsibility, should be confident in the knowledge that he/she can pursue governance service without needless concern about personal liability for breach of fiduciary duty and without creating an adver­ sarial relationship with management.

The perspectives shared in this educational resource are intended to assist the health care director in performing the important and necessary service of oversight of the corporate compliance program.

In so doing, it is hoped that fiduciary service will appear less daunting, and pro- vide a greater opportunity to “make a difference” in the delivery of health care.


CORPORATE RESPONSIBILITY AND CORPORATE COMPLIANCE 

II.

DUTY OF CARE 

Of the principal fiduciary obligations/duties owed by directors to their corporations, the one duty specifically implicated by corporate compliance programs is the duty of care.

As the name implies, the duty of care refers to the obligation of corporate directors to exercise the proper amount of care in their decision-making process.

State statutes that create the duty of care and court cases that interpret it usually are identical for both for-profit and non-profit corporations.

In most states, duty of care involves determining whether the directors acted (1) in “good faith,” (2) with that level of care that an ordinarily prudent person would exercise in like circumstances, and (3) in a manner that they reasonably believe is in the best interest of the corporation.

In analyzing whether directors have complied with this duty, it is necessary to address each of these elements separately.

The “good faith” analysis usually focuses upon whether the matter or transaction at hand involves any improper financial benefit to an individual, and/or whether any intent exists to take advantage of the corporation (a corol­ lary to the duty of loyalty).

The “reasonable inquiry” test asks whether the directors conducted the appropriate level of due diligence to allow them to make an informed decision.

In other words, directors must be aware of what is going on about them in the corporate business and must in appropriate circumstances make such reasonable inquiry, as would an ordinarily prudent person under similar circum­ stances.

And, finally, directors are obligated to act in a man­ ner that they reasonably believe to be in the best interests of the corporation.

This normally relates to the directors state of mind with respect to the issues at hand.

In considering directors fiduciary obligations, it is impor­ tant to recognize that the appropriate standard of care is not “perfection.”

Directors are not required to know every- thing about a topic they are asked to consider.

They may, where justified, rely on the advice of management and of outside advisors.

Furthermore, many courts apply the “business judgment rule” to determine whether a director’s duty of care has been met with respect to corporate decisions.

The rule provides, in essence, that a director will not be held liable for a decision made in good faith, where the director is disinterested, reasonably informed under the circum­ stances, and rationally believes the decision to be in the best interest of the corporation.

Director obligations with respect to the duty of care arise in two distinct contexts: 

• The decision-making function: 

The application of duty of care principles to a specific decision or a particular board action; and

 • The oversight function: 

The application of duty of care principles with respect to the general activity of the board in overseeing the day-to-day business operations of the corporation; i e , the exercise of reasonable care to assure that corporate executives carry out their man­ agement responsibilities and comply with the law.

Directors obligations with respect to corporate compliance programs arise within the context of that oversight func­ tion.

The leading case in this area, viewed as applicable to all health care organizations, provides that a director has two principal obligations with respect to the oversight func­ tion.

A director has a duty to attempt in good faith to assure that (1) a corporate information and reporting system exists, and (2) this reporting system is adequate to assure the board that appropriate information as to compliance with applicable laws will come to its attention in a timely manner as a matter of ordinary operations.2 In Caremark, the court addressed the circumstances in which corporate directors may be held liable for breach of the duty of care by failing to adequately supervise corporate employees whose mis­ conduct caused the corporation to violate the law.

In its opinion, the Caremark court observed that the level of detail that is appropriate for such an information system is a matter of business judgment.

The court also acknowl­edged that no rationally designed information and report­ ing system will remove the possibility that the corporation will violate applicable laws or otherwise fail to identify cor­ porate acts potentially inconsistent with relevant law.

Under these circumstances, a director’s failure to reason- ably oversee the implementation of a compliance pro- gram may put the organization at risk and, under extraor­ dinary circumstances, expose individual directors to per­ sonal liability for losses caused by the corporate non- 1 The other two core fiduciary duty principals are the duty of loyalty and the duty of obedience to purpose. 2 In re Caremark International Inc.

Derivative Litigation, 698 A 2d 959 (Del.

Ch. 1996).

A shareholder sued the Board of Directors of Caremark for breach of the fiduciary duty of care.

The lawsuit followed a multi-million dollar civil settlement and criminal plea relating to the payment of kickbacks to physicians and improper billing to federal health care programs. 2 compliance.3 Of course, crucial to the oversight function is the fundamental principle that a director is entitled to rely, in good faith, on officers and employees as well as corporate professional experts/advisors in whom the director believes such confidence is merited.

A director, however, may be viewed as not acting in good faith if he/she is aware of facts suggesting that such reliance is unwarranted.

In addition, the duty of care test involving reasonable inquiry has not been interpreted to require the director to exercise “proactive vigilance” or to “ferret out” corporate wrongdoing absent a particular warning or a “red flag.”

Rather, the duty to make reasonable inquiry increases when “suspicions are aroused or should be aroused;” that is, when the director is presented with extraordinary facts or circumstances of a material nature (e g , indications of financial improprieties, self-dealing, or fraud) or a major governmental investigation.

Absent the presence of suspi­ cious conduct or events, directors are entitled to rely on the senior leadership team in the performance of its duties.

Directors are not otherwise obligated to anticipate future problems of the corporation.

Thus, in exercising his/her duty of care, the director is obligated to exercise general supervision and control with respect to corporate officers.

However, once presented (through the compliance program or otherwise) with information that causes (or should cause) concerns to be aroused, the director is then obligated to make further inquiry until such time as his/her concerns are satisfacto­ rily addressed and favorably resolved.

Thus, while the cor­ porate director is not expected to serve as a compliance officer, he/she is expected to oversee senior manage­ ment’s operation of the compliance program.

III.

THE UNIQUE CHALLENGES OF HEALTH CARE ORGANIZATION DIRECTORS The health care industry operates in a heavily regulated environment with a variety of identifiable risk areas.

An effective compliance program helps mitigate those risks.

In addition to the challenges associated with patient care, health care providers are subject to voluminous and some- times complex sets of rules governing the coverage and reimbursement of medical services.

Because federal and state-sponsored health care programs play such a signifcant role in paying for health care, material non-compliance with these rules can present substantial risks to the health care provider.

In addition to recoupment of improper payments, the Medicare, Medicaid and other government health care programs can impose a range of sanctions against health care businesses that engage in fraudulent practices.

Particularly given the current “corporate responsibility” environment, health care organization directors should be concerned with the manner in which they carry out their duty to oversee corporate compliance programs.

Depending upon the nature of the corporation, there are a variety of parties that might in extreme circumstances seek to hold corporate directors personally liable for allegedly breaching the duty of oversight with respect to corporate compliance.

With respect to for-profit corporations, the most likely individuals to bring a case against the directors are corporate shareholders in a derivative suit, or to a limited degree, a regulatory agency such as the Securities and Exchange Commission.

With respect to non-profit corporations, the most likely person to initiate such action is the state attorney general, who may seek equitable relief against the director (e g removal) or damages.

It is also possible (depending upon state law) that a dissenting director, or the corporate member, could assert a derivative-type action against the directors allegedly respon­ sible for the “inattention,” seeking removal or damages.

Over the last decade, the risks associated with non-compli­ance have grown dramatically.

The government has dedicated substantial resources, including the addition of criminal investigators and prosecutors, to respond to health care fraud and abuse.

In addition to government investigators and auditors, private whistleblowers play an important role in identifying allegedly fraudulent billing schemes and other abusive practices.

Health care providers can be found liable for submitting claims for reimbursement in reckless disregard or deliberate igno­ rance of the truth, as well as for intentional fraud.

Because the False Claims Act authorizes the imposition of damages of up to three times the amount of the fraud and civil monetary penalties of $11,000 per false claim, record level fines and penalties have been imposed against individuals and health care organizations that have violated the law.

December 8, 2021

robinson, michael; levron, benjamin; malpractitioners

Dalbavancin



Dalbavancin (INN, trade names Dalvance in the US and Xydalba in the EU) is a novel second-generation lipoglycopeptide antibiotic medication. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).[2]

Dalbavancin is a semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin.[3] It is derived from a complex of glycopeptide antibiotics, referred to as A-40926, that is produced by a new strain of Actinomadura. Dalbavancin has been referred to in the scientific literature by a series of names: MDL-63397, A-!-1, BI-397, VER-001. These different labels reflected where the research had been carried out: MDL representing Merrell-Dow-Lepetit, where the initial complex was discovered; BI referring to BioSearch Italia where Dalbavancin itself was first synthesized; VER referring to Versicor (which Biosearch Italia merged with to create Vicuron Pharmaceuticals). The phase 1, 2 and 3 clinical trials were carried out of by Vicuron and the initial NDA filed. Vicuron was acquired by Pfizer in 2005, which decided to not further develop Dalbavancin at that time, subsequently selling the rights to Durata Therapeutics in 2009.

It possesses in vitro activity against a variety of Gram-positive pathogens[4][5] including MRSA and methicillin-resistant Staphylococcus epidermidis (MRSE).[6] It is a once-weekly, two-dose antibiotic, the rights to which Actavis acquired when it bought Durata Therapeutics in 2014.[7]

The U.S. Food and Drug Administration (FDA) approved dalbavancin in May 2014, for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by certain susceptible bacteria such as Staphylococcus aureus including methicillin-susceptible and methicillin-resistant strains of Streptococcus pyogenes, in intravenous dosage form.[8]

Medical uses

Dalbavancin is an antibiotic used to treat acute bacterial skin and skin structure infections (ABSSSI) in adults caused by susceptible Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA infections have become problematic in the community and in healthcare settings due to resistance to many available antibiotics.[9] Because dalbavancin has demonstrated efficacy against MRSA and other microorganisms to treat serious or life-threatening infections, it was the first drug approved as a Qualified Infectious Disease Product under the Generating Antibiotic Incentives Now (GAIN) act, which is part of the FDA Safety and Innovation Act.[10]

It has strong activity against many Gram-positive bacteria, including methicillin-sensitive and methicillin-resistant Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus.[11] Based on MIC data and other studies, dalbavancin is more potent and bactericidal and therefore requires lower concentrations than vancomycin against these organisms.[12] Dalbavancin also shows in vitro activity against vancomycin-susceptible Enterococcus faecium and Enterococcus faecalis.[11] Other Gram-positive organisms belonging to the Bacillus spp., Listeria spp., and Corynebacterium spp. may show in vitro susceptibility, and dalbavancin may exhibit activity against enterococci expressing the VanB or VanC phenotype of acquired resistance against vancomycin.[12][13] There is no clinically significant activity against Gram-negative bacteria.[12]

Two trials, DISCOVER 1 and DISCOVER 2, demonstrated noninferiority of dalbavancin compared to vancomycin/linezolid in the treatment of ABSSSI. Patients were randomly assigned to receive two doses of dalbavancin on days 1 and 8, or to receive intravenous vancomycin for at least 3 days with the option of switching to oral linezolid to complete 10 to 14 days of therapy. Investigators assessed the cessation of spread of infection-related erythema and the absence of fever at 48 to 72 hours as the primary endpoint and found that once-weekly dalbavancin was as effective as twice-daily intravenous vancomycin followed by oral linezolid.[14] This once-weekly dosing regimen may offer an advantageous treatment option compared to daily or twice-daily dosing.[10]

Contraindications

Hypersensitivity to dalbavancin can occur, causing issues such as skin reactions or anaphylaxis. Caution is advised for patients with known hypersensitivity to other glycopeptides. There is currently no data on cross-reactivity between dalbavancin and vancomycin.[11]

Side effects

The most common adverse reactions encountered in Phase II and Phase III trials were nausea (5.5%), headache (4.7%), and diarrhea (4.4%), as well as rash (2.7%) and itchiness (2.1%). Other less frequent but serious adverse reactions included hematologic disorders, hepatotoxicity, Clostridium difficile colitis, bronchospasm, infusion-related reactions including Red Man Syndrome, and anaphylactic shock.[11] In trials, dalbavancin was associated with higher rates of hemorrhagic events compared to comparator groups and should be a precaution in patients undergoing surgery or taking anticoagulants.[12] Patients on dalbavancin also had post-baseline alanine aminotransferase (ALT) levels that were 3 times the upper normal limit, some even having elevations 10 times the upper normal limit; however, eight of the twelve dalbavancin-treated patients had comorbid conditions that could affect their ALT, compared to only one patient in the comparator group.[11] There is no evidence of ototoxicity associated with dalbavancin.[13]

Drug interaction

Clinical drug-drug interactions with dalbavancin have not been studied, and dalbavancin does not appear to interact with cytochrome P450 substrates, inhibitors, or inducers. It was found to have an in vitro synergistic interaction with the antimicrobial oxacillin, but the clinical significance of this interaction has yet to be established.[11]

Pregnancy and lactation

Use of dalbavancin in pregnant women has not been studied sufficiently and should only occur when the potential benefit outweighs the potential risk to the fetus. Animal studies did not show embryo or fetal toxicity at doses that were 1.2 and 0.7 times the human dose. However, delayed fetal maturation was observed at a dose that was 3.5 times the human dose. While dalbavancin is excreted in rat milk, it is unknown if it is excreted in human milk. It should be used in nursing mothers only when the potential benefit exceeds the potential risk.[11] There is no evidence in animals of teratogenicity.[13]

Production and composition

Dalbavancin is manufactured by fermentation of a selected Nonomuraea strain to generate the natural glycopeptide complex A-40926. This precursor is then selectively esterified at the carboxyl group of its sugar moiety, its peptidyl carboxyl group is amidated and the ester of the N-acylaminoglucuronic acid carboxyl group is saponified.[15] The outcome is a compound mixture of two closely related structural families — A and B — that can be further subdivided into a total of five subtypes (see table below).[1] At least ten different dalbavancin components have been described, of which the B0 component makes up around 80–98 wt%.[15]

Mechanism of action

Dalbavancin is a lipoglycopeptide belonging in the same glycopeptide class as vancomycin. Similar to other glycopeptides, dalbavancin exerts its bactericidal effect by disrupting cell wall biosynthesis. It binds to the D-alanyl-D-alanyl residue on growing peptidoglycan chains and prevents transpeptidation from occurring, preventing peptidoglycan elongation and cell wall formation. Dalbavancin also dimerizes and anchors itself in the lipophilic bacterial membrane, thereby increasing its stability in the target environment and its affinity for peptidoglycan.[12]

Antimicrobial activity correlates with the ratio of area under the concentration-time curve to minimum inhibitory concentration for Staphylococcus aureus.[11]

Metabolism

When evaluated by in vitro studies, the metabolism of dalbavancin was minimally impacted by the human hepatic CYP450 system.[16] Further investigations with either inducers or inhibitors of this enzyme system demonstrated no changes in the elimination or clearance of dalbavancin, and the metabolism of model compounds of these CYP systems was not altered by the dalbavancin. Hydroxy-dalbavancin, a minor metabolite that has only been identified in urine, was also not changed in its formation or elimination with these enzyme models.[16][17]

History

Dalbavancin has undergone a phase-III clinical trial for adults with complicated skin infections, but in December 2007, the FDA said more data were needed before approval.[7] On September 9, 2008, Pfizer announced it will withdraw all marketing applications to conduct another phase-III clinical trial.[18] Durata Therapeutics acquired the rights to dalbavancin in December 2009, and has initiated two new phase-III clinical trials for treatment of ABSSSIs.[19] Preliminary results in 2012 were promising.[20]

About 1,289 adults with ABSSSI were given dalbavancin or vancomycin randomly, and dalbavancin was found to exhibit efficacy comparable to vancomycin.[21]

In May 2014, dalbavancin was approved by the FDA for use in the US for ABSSSIs, including MRSA and Streptococcus pyogenes infections.

References

  1. ^ Jump up to: a b European Medicines Agency (EMA) assessment of Dalbavancin http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002840/WC500183871.pdf
  2. ^ Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration
  3. ^ Scheinfeld N (May 2006). "Dalbavancin: a review for dermatologists". Dermatology Online Journal. 12 (4): 6. PMID 17083861.
  4. ^ Chen AY, Zervos MJ, Vazquez JA (May 2007). "Dalbavancin: a novel antimicrobial". International Journal of Clinical Practice. 61 (5): 853–63. doi:10.1111/j.1742-1241.2007.01318.x. PMC 1890846. PMID 17362476.
  5. ^ Das B, Sarkar C, Biswas R, Pandey S (January 2008). "Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens". Pakistan Journal of Pharmaceutical Sciences. 21 (1): 78–87. PMID 18166524.
  6. ^ Dalbavancin: A Novel Lipoglycopeptide Antibacterial
  7. ^ Jump up to: a b UPDATE 1-Pfizer says US FDA wants more data on antibiotic. Dec 2007
  8. ^ US FDA approves drug Dalvance containing Dalbavancin
  9. ^ Centers for Disease Control and Prevention - Methicillin-Resistant Staphylococcus aureus (MRSA) infections. https://www.cdc.gov/mrsa/
  10. ^ Jump up to: a b Dalbavancin: First I.V. antibiotic for acute bacterial skin infections. http://www.pharmacist.com/dalbavancin-first-iv-antibiotic-acute-bacterial-skin-infections
  11. ^ Jump up to: a b c d e f g h Dalvance (dalbavancin) for injection Full Prescribing Information. http://content.stockpr.com/duratatherapeutics/files/docs/Dalvance+APPROVED+USPI.PDF
  12. ^ Jump up to: a b c d e Bennet JW, Lewis JS, Ellis MW (2008). "Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review." Therapeutics and Clinical Risk Management 4 (1): 31-40. PMC 2503664.
  13. ^ Jump up to: a b c FDA Briefing Document: Anti-Infective Drugs Advisory Committee Meeting. NDA 21-883: Dalvance (Dalbavancin) for Injection. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM390792.pdf
  14. ^ Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW (June 2014). "Once-weekly dalbavancin versus daily conventional therapy for skin infection". The New England Journal of Medicine. 370 (23): 2169–79. doi:10.1056/NEJMoa1310480. PMID 24897082.
  15. ^ Jump up to: a b US patent 7119061
  16. ^ Jump up to: a b Leuthner KD, Buechler KA, Kogan D, Saguros A, Lee HS (June 2016). "Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)". Therapeutics and Clinical Risk Management. 12: 931–40. doi:10.2147/TCRM.S86330. PMC 4907732. PMID 27354809.
  17. ^ Buckwalter M, Dowell JA (November 2005). "Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide". Journal of Clinical Pharmacology. 45 (11): 1279–87. doi:10.1177/0091270005280378. PMID 16239361. S2CID 42875399.
  18. ^ "Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial" (Press release). Pfizer Inc. 2008-09-09. Retrieved 2008-09-11.
  19. ^ Durata Begins Dalbavancin Study Enrollment. Drug Discovery & Development - October 05, 2011.
  20. ^ Durata Therapeutics Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI
  21. ^ Dalvance’s safety and efficacy clinical trial ABSSSI, Results showed Dalvance was as effective as vancomycin

External links[edit]

"Dalbavancin". Drug Information Portal. U.S. National Library of Medicine.

 

December 7, 2021

USPS Certified FMOLHS Certified Mail Fraud from Mark Zielinski, M.D. Involuntary Beneficiary Disenrollment Violation of Medicaid / CMS, LSU Board of Supervisors, LA State Civil Service Bylaws






 

Mark Zielinski, M.D.,

FMOLHS

Our Lady of the Lake Physicians Group

5131 O'Donovan Dr., STE. 3000

Baton Rouge, LA 70808

Certified Mail

Ph: (225) 374-0400

 

Certified Letter from Mark Zielinski, M.D., postmarked June 14, 2021 

 

*ante-dated June 2, 2021 

 

forensic patient record refractory provision, 1 month grace period for "Emergency Only" treatment--a counterfeit, forgery, and mail fraud (issued from a Federally designated institution, through malicious intent to involuntarily disenroll Medicaid ACA beneficiary from Provider care, and moreover, from his entire practice.

 

Zielinski and FMOLHS, OLOL Clinic, my Physician and Healthcare provider committed the same  Federal Criminal crime for which their recent CEO / President had been convicted and jailed (John Paul Funes), in a scam involving their own pediatric cancer patients, gift cards, 1 million dollars, seven years, LSU Footbal player bribes, and their inability to discover it themselves. 

 

To  shave off a couple weeks of already improperly omitted abidance to AMA Medical Ethics bylaws, guidelines, and best practices. 

 


 

if found guilty, violation of state or federal bylaws

 

censure, suspension, debarment, rescission, removal of physician ability to practice medicine, disqualification of LSU academic coursework, curricula, supervision, and viability of credentialed student MATCH, resulting in Examiner required re-audit,  application (see AMA website).

 

updated policies before last resort termination, over a passing remark made on clinic answer machine, commenting on vagaries of monthly reminders to refill prescriptions of long-standing order

 

The board governance structure was designed to allow for a mechanism, separate from FMOLHS, through which content can be brought forward for independent review; namely through the creation of an Oversight Board Trust (“the trust”) and the Oversight Board Limited Liability Corporation (“the LLC”).

 

The trust was created to facilitate the creation, funding, management, and oversight of a structure that will permit and protect the operation of the board.

 

And the LLC is a legal entity created by the trust to hold the contractual relationship with board members and hire a full-time staff (“the administration”).

 

Importantly, the bylaws detail the relationship between all those who have a stake in the board’s success, including FMOLHS, Inc., LSU Board of Supervisors (collectively referred to as “Arrangement”), the board itself, the people who submit requests for the board’s review, and the trust:

 

 1 outlines the respective roles of the board’s membership, its committees, and administration, while setting out procedures for case review and communications.

 

 2 reaffirms FMOLHS commitment to the board and establishes procedures for its case submission, decision implementation, and response to policy advisory opinions.

 

3 explains the procedures by which people can submit cases to the board.

 

4 provides an overview of the composition and duties of the trust.

 

5 sets a process for amendments to the bylaws.

 

In cases where there is a potential conflict between interpretations of the charter and bylaws, the charter shall prevail. The bylaws will be operational upon their respective adoption by FMOLHS, the trustees and members of the board.

 

Subsequent amendments can be adopted in accordance with 5, herein.

 

5

 

O V E R S I G H T B O A R D B Y L A W S

 

1: Oversight Board

 

Section 1.

 

Members

 

The board is administered by an LLC established by the trust. It will be composed of a diverse set of members whose names will be public. They will exercise neutral, independent judgment and render decisions impartially.

 

2 To manage its operations, the board will have officers and committees, which will meet periodically to conduct business, including case and member selection.

 

3 1.1

 

Officers

 

The officers of the board will initially consist of at least three (3) co-chairs. Thereafter, the board may periodically assess its officer structure and create or appoint additional positions, based on its operational requirements.

 

1.1.1

 

Officer Duties

 

Co-chairs will have the same duties and obligations as the rest of the board, in addition to their duties and obligations as officers. The co-chairs will supervise the affairs of the board (e.g. calling and presiding over meetings).

 

4 They will set agendas for meetings; oversee the voting on board-related business, and ensure that minutes are documented and circulated to all members. They will also rotate as chairs of the case selection and membership committees, as described below. The co-chairs may participate in the management of the board’s administration, which will include hiring staff members, developing an annual budget, and arranging general services for the board.

 

5 In addition, the co-chairs will have ex-officio seats at meetings of the trustees and will report to board members on the outcomes of those discussions. The board may also request that the co-chairs take on additional duties, such as setting procedural rules, as needs arise. Any actions that may be taken by the co-chairs of the board will require the approval of a majority of the co-chairs of the board.

 

1.1.2 Officer Selection and Term

 

FMOLHS will select the initial co-chairs. Thereafter, the outgoing co-chairs, in consultation with the entire board, will select their replacements, who will then be sent to the trustees for confirmation. In selecting co-chairs, preference should be given to members who have completed at least one year of service on the board. If the board determines that it would like to elect other officers, those individuals can be elected by a majority vote of the board itself.

 

 

O V E R S I G H T B O A R D B Y L A W S

 

Co-chairs and other officers will serve initial terms of three years, up to a maximum of two terms total, or until their resignation or removal. The board will confirm renewals and/or elect officers during their meetings.

 

6 Upon the confirmation of co-chairs to a second term, those terms will be staggered in order to ensure a smooth transition of leadership on the board.

 

7 Second terms will be staggered to ensure that the co-chairs do not leave office concurrently.

 

1.1.3 Officer Resignation, Removal, and Vacancies

 

Co-chairs and other officers may step down from their position as board officers at any time by giving written notice to the director of the oversight board (“the director”); they may also have their responsibilities as co-chairs revoked by a two-thirds vote of the board, which must be approved by the trustees. Removal as an officer will not automatically result in removal from the board. Ordinary vacancies, however occurring, may be filled by a majority vote of the board on a temporary basis, until the next semi-annual meeting of the board.

 

1.2 Committees

 

The board will have a membership committee and case selection committee. Each committee shall be chaired by a single co-chair. The board may form other committees, and decide their leadership structure, through a majority vote, as needed.

 

1.2.1 Case Selection Committee

 

Members of the case selection committee will serve three month terms on a rotating basis. Co-chairs will rotate leadership of this committee every three months. The case selection committee will set criteria (e.g. importance and precedential impact) for the cases that the board will prioritize and select for review, which may change over time. Decisions of the committee will be by majority vote, subject to override by a majority vote of the full board. The case selection committee will document its selection criteria, as well as the volume and types of cases that: FMOLHS has submitted; people have submitted; and the board has selected for review.

 

8 1.2.2 Membership Committee

 

Members of the membership committee will serve  Images of Doug Meet's blackballing by FMOLHS & OLOLRMC & Our Lady of the Lake Physicians Group, Family Center at O'Donovan / Center for Psychiatric Services

 



 

US Congress Long Reads Mental health Social media Baton Rouge, Louisiana, Constructive Eviction, Self-Help, Violation, Federal, CDC, Moratorium

 

images were supplied and Getty Stock. All are subject to copyright.

Hawaiian bed needs a new duvet- on the bar in the living room. Rocco Siefredi y las putas limpian a las tres de la madrugada con el preseleccionada.

 



La cama hawaiana necesita un edredón nuevo en la barra de la sala.

"¿Considerarán el vino blanco o la cama Tinto Brass?"
 

Rocco Siefriedi y las putas limpian mi habitación a las tres de la madrugada con el jovencito preseleccionado.


¿Amabilidad, benevolencia, facilidad de atención?

De mis invocaciones lloverán las porciones de tres almohadas.
Pisos, por favor.

    






Yo, durante semanas, bajo el fregadero, le rezo a la bañera, cuyo desagüe está atascado, por la aparición de finos cabellos rubios, cuya presencia sea un problema secundario, y su mentira un paso. 

 

Hawaiian bed needs a new duvet- on the bar in the living room.

"Will they consider the white wine or the Tinto Brass bed?"


Rocco Siefriedi and the whores clean my room at three in the morning with the short-listed youngster.

Kindness, benevolence, ease of attention?

The servings of three pillows will rain from my invocations.
Flats, please.
   I, for weeks, under the sink, pray to the bathtub, whose drain is clogged, for appearance of fine blond hairs, whose presence be side issue, and its lie a go.